Intact Breast Lesion Excision System
Breast Biopsy Applications
Breast Biopsy Applications
The Intact™ breast lesion excision system is an automated, percutaneous biopsy device capable of delivering a surgical quality specimen for histological review of breast abnormalities. Intact is uniquely suited to preserve lesion architecture within the biopsy sample, providing an opportunity for pathological assessment and the potential avoidance of an open surgical biopsy. Operated under ultrasound or stereotactic imaging, the Intact breast lesion excision system provides high-quality, diagnostic sampling of palpable and non-palpable breast abnormalities.
The Intact breast lesion excision system is indicated to provide tissue samples for: diagnostic sampling of breast abnormalities, histologic examination with partial or complete removal of an imaged abnormality, and histologic examination with partial removal of a palpable abnormality.
The Intact breast lesion excision system is intended to preserve lesion architecture in samples with a diameter of 12–20 mm.
Please see Indications, Safety, and Warnings for more info.
Utilizing radiofrequency (RF) energy, Intact deploys a wire capture basket to circumferentially surround the targeted lesion. During the capture sequence RF energy cuts and coagulates tissue, isolating the contiguous sample for removal through a 6–8 mm incision. The system can be operated directly from the handle or by using a foot pedal based on physician preference.
Intact 12 mm, 15 mm, and 20 mm wands
Find these technical manuals in the Medtronic Manual Library, in the product labeling supplied with each device, or by filling in the contact form on the right.
When the sampled abnormality is not histologically benign, it is essential that the tissue margins be examined for completeness of removal using standard surgical procedures.
Complete Excision Rates were evaluated as a surrogate measure to assess the ability to remove sufficient, undisrupted tissue to preserve tissue architecture and to permit a definitive diagnosis. Success rate dependent upon lesion size/location and wand sized used during the procedure. Success rates in the literature range from 49–100%.
Whitworth P, Simpson J, et al. Definitive Diagnosis for High-Risk Breast Lesions Without Open Surgical Excision: The Intact Percutaneous Excision Trial (IPET). Ann Surg Oncl. 2009; 18:3047-3052
Seror, Jean-Yves. “Predictive factors for complete excision and underestimation of one-pass en bloc excision of non-palpable breast lesions with the Intact”. European Journal of Radiology (2011).
Razek, Naglaa, et al. Percutaneous breast lesion excision system (BLES): A new tool for complete closed excision of high risk lesions (Egyptian experience). The Egyptian Journal of Radiology and Nuclear Medicine 2013;44:383-389.
Allen SD, Nerurkar A, Della Rovere GU. The breast lesion excision system (BLES): a novel technique in the diagnostic and therapeutic management of small indeterminate breast lesions? European Radiology 2011 May; 21(5):919-924.
Medtronic and the Medtronic logo are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.